Vanguard Group’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-821,457
| Closed | -$15.6M | – | 4239 |
|
|
2019
Q1 | $15.6M | Buy |
821,457
+18,479
| +2% | +$300K | ﹤0.01% | 2617 |
|
|
2018
Q4 | $10.8M | Buy |
802,978
+87,962
| +12% | +$983K | ﹤0.01% | 2737 |
|
|
2018
Q3 | $7.94M | Buy |
+715,016
| New | +$7.15M | ﹤0.01% | 3034 |
|
|
2017
Q1 | – | Sell |
-721,743
| Closed | -$3.54M | – | 4124 |
|
|
2016
Q4 | $3.54M | Sell |
721,743
-3,874
| -0.5% | -$19.8K | ﹤0.01% | 3180 |
|
|
2016
Q3 | $3.6M | Buy |
725,617
+8,465
| +1% | +$43.3K | ﹤0.01% | 3153 |
|
|
2016
Q2 | $3.65M | Sell |
717,152
-3,202
| -0.4% | -$17.2K | ﹤0.01% | 3121 |
|
|
2016
Q1 | $4.11M | Buy |
720,354
+22,378
| +3% | +$156K | ﹤0.01% | 3065 |
|
|
2015
Q4 | $7.25M | Buy |
697,976
+22,766
| +3% | +$309K | ﹤0.01% | 2814 |
|
|
2015
Q3 | $12.5M | Buy |
675,210
+29,216
| +5% | +$564K | ﹤0.01% | 2487 |
|
|
2015
Q2 | $12.6M | Sell |
645,994
-967
| -0.1% | -$17.1K | ﹤0.01% | 2558 |
|
|
2015
Q1 | $11.4M | Buy |
646,961
+22,591
| +4% | +$380K | ﹤0.01% | 2585 |
|
|
2014
Q4 | $9.98M | Buy |
624,370
+11,247
| +2% | +$151K | ﹤0.01% | 2538 |
|
|
2014
Q3 | $7.72M | Buy |
613,123
+27,791
| +5% | +$396K | ﹤0.01% | 2612 |
|
|
2014
Q2 | $9.14M | Sell |
585,332
-3,040
| -0.5% | -$44.7K | ﹤0.01% | 2545 |
|
|
2014
Q1 | $7.72M | Buy |
588,372
+40,285
| +7% | +$630K | ﹤0.01% | 2609 |
|
|
2013
Q4 | $8.81M | Buy |
548,087
+32,068
| +6% | +$511K | ﹤0.01% | 2522 |
|
|
2013
Q3 | $8.59M | Sell |
516,019
-10,673
| -2% | -$158K | ﹤0.01% | 2469 |
|
|
2013
Q2 | $5.3M | Buy |
+526,692
| New | +$5.53M | ﹤0.01% | 2633 |
|
Other funds holding OSIR
Vanguard Group's OSIR Position: Q2 2019 in Review
Vanguard Group sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 821,457 shares — an estimated $15.6M sold.
Vanguard Group first reported a position in OSIR in Q2 2013 and held it in 18 quarters. The position peaked at $15.6M in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Vanguard Group reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Vanguard Group sold 821,457 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $15.6M.
- Vanguard Group first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
- Vanguard Group's Osiris Therapeutics, Inc. Common Stock position peaked at $15.6M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Vanguard Group's 13F filing for Q2 2019, filed 14 Aug 2019.